The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders
Open accessAbstract
Importance: Recent studies have reported a higher relapse rate following an initial inflammatory demyelinating disorder in pediatric patients with persistent seropositivity of antibodies targeting myelin oligodendrocyte glycoprotein (MOG-IgG1). To date, the clinical implications of longitudinal MOG-IgG1 seropositivity using live cell assays with IgG1 secondary antibodies in adults after acute disseminated encephalomyelitis (ADEM) are unknown. Objective: To determine whether MOG-IgG1 serostatus (transient vs persistent) and titer change over time provide clinical utility in predicting the likelihood of relapse after ADEM. Design, Setting, and Participants: This cohort study identified patients with an initial diagnosis of ADEM evaluated at a single referral center between January 1, 1990, and October 1, 2017. Fifty-one patients were included, including 31 children and 20 adults. Longitudinal serologic testing was performed detecting autoantibodies targeting aquaporin 4 (AQP4-IgG) and MOG-IgG1 with clinically validated fluorescence-activated cell sorting assays. Patients were divided into 3 cohorts: persistent seropositivity, transient seropositivity, and seronegativity. Main Outcomes and Measures: Clinical demographic characteristics, longitudinal AQP4-IgG and MOG-IgG1 serostatus, titers, relapses, use of immunotherapy, and Expanded Disability Status Scale score at follow-up. Results: Of 51 patients presenting with an initial diagnosis of ADEM, 20 (39%) were adult, 24 (47%) were female, and ages ranged from 12 months to 57 years. Seventeen patients fulfilled criteria for persistent seropositivity; of those, 8 of 9 children (89%) and 7 of 8 adults (88%) had at least 1 relapse after median (range) follow-up periods of 75 (15-236) months and 39 (9-161) months, respectively. Eight patients (16%), including 4 adults, fulfilled criteria for transient seropositivity; of those, no children and 1 of 4 adults (25%) relapsed after median (range) follow-up periods of 32 (24-114) months and 16 (13-27) months, respectively. Of 24 patients with AQP4-IgG and MOG-IgG seronegativity, 6 of 17 children (35%) and 2 of 7 adults (29%) had at least 1 relapse after median (range) follow-up periods of 36 (3-203) months and 34 (15-217) months, respectively. There were only 2 patients, including 1 adult, with AQP4-IgG seropositivity, and both relapsed. The hazard ratio for relapses in those with persistent MOG-IgG1 positivity compared with AQP4-IgG and MOG-IgG1 seronegativity was 3.1 (95% CI, 1.1-8.9; P = .04) in children and 5.5 (95% CI, 1.4-22.5; P = .02) in adults. Immunotherapy was used in 5 of 9 children (56%) and 6 of 8 adults (75%) with persistent seropositivity and in 3 of 17 children (18%) and 1 of 7 adults (14%) with AQP4-IgG and MOG-IgG seronegativity. Conclusions and Relevance: Relapse occurred in 15 of 17 patients (88%) with persistent MOG-IgG1 seropositivity after ADEM; only 1 patient with transient seropositivity experienced relapse. Our data extend the clinical utility of MOG-IgG1 serological testing to adult patients and highlights that longitudinal serologic evaluation of MOG-IgG1 could help predict disease course and consideration of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis
Dubey, D., Pittock, S. J., Kelly, C. R., McKeon, A., Lopez‐Chiriboga, A. S., Lennon, V. A., Gadoth, A., Smith, C. Y., Bryant, S. C., Klein, C. J., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25131 · Cited by 777
Self-citationClinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., et al. (2017) · Brain · doi:10.1093/brain/awx276 · Cited by 740
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
Weinshenker, B. G., Wingerchuk, D. M., Vukusic, S., Linbo, L., Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2006) · Annals of Neurology · doi:10.1002/ana.20770 · Cited by 588
Self-citationRamanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 390
The spectrum of MOG autoantibody-associated demyelinating diseases
Reindl, M., Di Pauli, F., Rostásy, K., & Berger, T. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.118 · Cited by 375
Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome
Hennes, E.-M., Baumann, M., Schanda, K., Anlar, B., Bajer-Kornek, B., Blaschek, A., Brantner-Inthaler, S., Diepold, K., Eisenkölbl, A., Gotwald, T., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004312 · Cited by 341
Brilot, F., Dale, R. C., Selter, R. C., Grummel, V., Reddy Kalluri, S., Aslam, M., Busch, V., Zhou, D., Cepok, S., & Hemmer, B. (2009) · Annals of Neurology · doi:10.1002/ana.21916 · Cited by 322
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis
Pröbstel, A. K., Dornmair, K., Bittner, R., Sperl, P., Jenne, D., Magalhaes, S., Villalobos, A., Breithaupt, C., Weissert, R., Jacob, U., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c0b1 · Cited by 306
Neuromyelitis Spectrum Disorders
Weinshenker, B. G., & Wingerchuk, D. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.12.014 · Cited by 286
Self-citationHöftberger, R., Sepulveda, M., Armangue, T., Blanco, Y., Rostásy, K., Cobo Calvo, A., Olascoaga, J., Ramió-Torrentà, L., Reindl, M., Benito-León, J., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514555785 · Cited by 285
Ramanathan, S., Dale, R. C., & Brilot, F. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.12.004 · Cited by 281
Zamvil, S. S., & Slavin, A. J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000062 · Cited by 276
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Kleiter, I., Ruprecht, K., Asgari, N., Pitarokoili, K., Borisow, N., Hümmert, M. W., Trebst, C., Pache, F., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0719-z · Cited by 252
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Kim, S.-M., Woodhall, M. R., Kim, J.-S., Kim, S.-J., Park, K. S., Vincent, A., Lee, K.-W., & Waters, P. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000163 · Cited by 232
Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases
Di Pauli, F., Mader, S., Rostasy, K., Schanda, K., Bajer-Kornek, B., Ehling, R., Deisenhammer, F., Reindl, M., & Berger, T. (2011) · Clinical Immunology · doi:10.1016/j.clim.2010.11.013 · Cited by 200
Young, N. P., Weinshenker, B. G., Parisi, J. E., Scheithauer, B., Giannini, C., Roemer, S. F., Thomsen, K. M., Mandrekar, J. N., Erickson, B. J., & Lucchinetti, C. F. (2010) · Brain · doi:10.1093/brain/awp321 · Cited by 186
Self-citationHistopathology and clinical course of MOG-antibody-associated encephalomyelitis
Spadaro, M., Gerdes, L. A., Mayer, M. C., Ertl-Wagner, B., Laurent, S., Krumbholz, M., Breithaupt, C., Högen, T., Straube, A., Giese, A., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.164 · Cited by 176
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
Pröbstel, A.-K., Rudolf, G., Dornmair, K., Collongues, N., Chanson, J.-B., Sanderson, N. S., Lindberg, R. L., Kappos, L., de Seze, J., & Derfuss, T. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0256-1 · Cited by 169
Acute Disseminated Encephalomyelitis: Current Understanding and Controversies
Young, N., Weinshenker, B., & Lucchinetti, C. (2008) · Seminars in Neurology · doi:10.1055/s-2007-1019130 · Cited by 165
Self-citationBrain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
Juryńczyk, M., Tackley, G., Kong, Y., Geraldes, R., Matthews, L., Woodhall, M. R., Waters, P. J., Küker, W., Craner, M. J., Weir, A., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314005 · Cited by 165
Rostasy, K. M., Mader, S., Hennes, E. M., Schanda, K., Gredler, V., Guenther, A., Blaschek, A., Korenke, C., Pritsch, M., Pohl, D., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512470310 · Cited by 163
Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases
Hyun, J., Woodhall, M. R., Kim, S., Jeong, I. H., Kong, B. S., Kim, G., Kim, Y., Park, M. S., Irani, S. R., Waters, P. J., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315998 · Cited by 160
Sepúlveda, M., Armangué, T., Martínez‐Hernández, E., Arrambide, G., Solà‐Valls, N., Sabater, L., Téllez, N., Midaglia, L. S., Ariño, H., Peschl, P., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8147-7 · Cited by 136
Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis
Nakajima, H., Motomura, M., Tanaka, K., Fujikawa, A., Nakata, R., Maeda, Y., Shima, T., Mukaino, A., Yoshimura, S., Miyazaki, T., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007766 · Cited by 85
Wong, Y. Y. M., Hacohen, Y., Armangué, T., Wassmer, E., Verhelst, H., Hemingway, C. A., van Pelt, E. D., Catsman‐Berrevoets, C. E., Hintzen, R. Q., Deiva, K., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13602 · Cited by 66
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?
Pittock, S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.9
Self-citation
Cited by
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00431-8 · Cited by 1,246
Self-citationMyelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Myelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A.-K., Aktas, O., Alexopoulos, H., Amato, M.-P., Asgari, N., Banwell, B., Bennett, J., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 543
Self-citationDubey, D., Pittock, S. J., Krecke, K. N., Morris, P. P., Sechi, E., Zalewski, N. L., Weinshenker, B. G., Shosha, E., Lucchinetti, C. F., Fryer, J. P., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4053 · Cited by 384
Self-citation
Metadata
- Authors
- López-Chiriboga, A. S., Majed, M., Fryer, J., Dubey, D., McKeon, A., Flanagan, E. P., Jitprapaikulsan, J., Kothapalli, N., Tillema, J.-M., Chen, J., Weinshenker, B., Wingerchuk, D., Sagen, J., Gadoth, A., Lennon, V. A., Keegan, B. M., Lucchinetti, C., & Pittock, S. J.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-11-01
- Volume
- 75
- Issue
- 11
- Pages
- 1355
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2884356229
- Cited by
- 410
- References
- 28
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.